Human Papillomavirus Protein E7 (E7) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Human Papillomavirus Protein E7 (E7) – Pipeline Review, H1 2018’, provides in depth analysis on Human Papillomavirus Protein E7 (E7) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Women's Health and Infectious Disease under development targeting Human Papillomavirus Protein E7 (E7).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E7 (E7)

– The report reviews Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics and enlists all their major and minor projects

– The report assesses Human Papillomavirus Protein E7 (E7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Human Papillomavirus Protein E7 (E7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E7 (E7)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E7 (E7) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Abion Inc

Advaxis Inc

Bioleaders Corp

BioNTech AG

Cancer Research Technology Ltd

Etubics Corp

Formune SL

Genexine Inc

Hookipa Biotech AG

iBio Inc

Immunovaccine Inc

Inovio Pharmaceuticals Inc

MedImmune LLC

Selecta Biosciences Inc

Touchlight Genetics Ltd

Transgene SA

VLPbio

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Human Papillomavirus Protein E7 (E7) Overview

Human Papillomavirus Protein E7 (E7) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Human Papillomavirus Protein E7 (E7) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Human Papillomavirus Protein E7 (E7) Companies Involved in Therapeutics Development

Abion Inc

Advaxis Inc

Bioleaders Corp

BioNTech AG

Cancer Research Technology Ltd

Etubics Corp

Formune SL

Genexine Inc

Hookipa Biotech AG

iBio Inc

Immunovaccine Inc

Inovio Pharmaceuticals Inc

MedImmune LLC

Selecta Biosciences Inc

Touchlight Genetics Ltd

Transgene SA

VLPbio

Human Papillomavirus Protein E7 (E7) Drug Profiles

ABN-301 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit E7 for HPV Associated Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aptamer to Target HPV E7 Protein for Cervical Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

axalimogene filolisbac Drug Profile

Product Description

Mechanism Of Action

R&D Progress

axalimogene filolisbac second generation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLSILSB-710c Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BVAC-C Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CerviVax Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUE-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUE-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNA Vaccine to Target E7 for HPV Associated Cancers Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPXE-7 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDA-HPVE7 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-041 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLBL-101c Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-188E Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [Serotype 16] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [serotypes 16] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-3106 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-0457 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Vector Vaccine to Target Human Papillomavirus Protein E7 for HPV Associated Cervical Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SEL-701 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TA-CIN Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-4001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tricurin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTFC-E7SH Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target E6 and E7 for Human Papillomavirus (HPV) Associated Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HPV E7 Protein for Cervical Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VGX-3100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vvax-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Human Papillomavirus Protein E7 (E7) Dormant Products

Human Papillomavirus Protein E7 (E7) Discontinued Products

Human Papillomavirus Protein E7 (E7) Product Development Milestones

Featured News & Press Releases

Feb 13, 2018: Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union

Feb 12, 2018: Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer

Jan 29, 2018: Data Highlighting Advaxis Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies

Jan 08, 2018: Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2

Dec 05, 2017: Cue Biopharma Announces Appointment of Colin Sandercock as Senior Vice President and General Counsel

Nov 29, 2017: Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy

Nov 27, 2017: Inovio Pharmaceuticals Provides Update on Cancer Drug Candidate INO-3112

Nov 10, 2017: Inovio Pharmaceuticals Presents data on MEDI0457 at Society for Immunotherapy of Cancer Conference

Sep 19, 2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers

Jul 13, 2017: Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders

Jun 26, 2017: Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017

Jun 19, 2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer

Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer

May 18, 2017: Advaxis to Host Investor & Analyst Day on June 12

May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1)

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Abion Inc, H1 2018

Pipeline by Advaxis Inc, H1 2018

Pipeline by Bioleaders Corp, H1 2018

Pipeline by BioNTech AG, H1 2018

Pipeline by Cancer Research Technology Ltd, H1 2018

Pipeline by Etubics Corp, H1 2018

Pipeline by Formune SL, H1 2018

Pipeline by Genexine Inc, H1 2018

Pipeline by Hookipa Biotech AG, H1 2018

Pipeline by iBio Inc, H1 2018

Pipeline by Immunovaccine Inc, H1 2018

Pipeline by Inovio Pharmaceuticals Inc, H1 2018

Pipeline by MedImmune LLC, H1 2018

Pipeline by Selecta Biosciences Inc, H1 2018

Pipeline by Touchlight Genetics Ltd, H1 2018

Pipeline by Transgene SA, H1 2018

Pipeline by VLPbio, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports